H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on TransCode Therapeutics (RNAZ – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $0.40.
According to TipRanks, Bodnar is an analyst with an average return of -13.8% and a 24.07% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Imunon, and SQZ Biotechnologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TransCode Therapeutics with a $6.00 average price target.
See today’s best-performing stocks on TipRanks >>
Based on TransCode Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $4.29 million. In comparison, last year the company had a GAAP net loss of $2.33 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Read More on RNAZ:
- Transcode Therapeutics announces eIND submission to U.S. FDA
- TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
- TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
- TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
